281 related articles for article (PubMed ID: 26934557)
1. CD40-activated B cells induce anti-tumor immunity in vivo.
Wennhold K; Weber TM; Klein-Gonzalez N; Thelen M; Garcia-Marquez M; Chakupurakal G; Fiedler A; Schlösser HA; Fischer R; Theurich S; Shimabukuro-Vornhagen A; von Bergwelt-Baildon M
Oncotarget; 2017 Apr; 8(17):27740-27753. PubMed ID: 26934557
[TBL] [Abstract][Full Text] [Related]
2. The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo.
Deronic A; Nilsson A; Thagesson M; Werchau D; Enell Smith K; Ellmark P
Cancer Immunol Immunother; 2021 Dec; 70(12):3629-3642. PubMed ID: 33948686
[TBL] [Abstract][Full Text] [Related]
3. CD40-activated B cells as antigen-presenting cells: the final sprint toward clinical application.
Wennhold K; Shimabukuro-Vornhagen A; Theurich S; von Bergwelt-Baildon M
Expert Rev Vaccines; 2013 Jun; 12(6):631-7. PubMed ID: 23750793
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.
Ceglia V; Zurawski S; Montes M; Kroll M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
Front Immunol; 2021; 12():786144. PubMed ID: 35095862
[TBL] [Abstract][Full Text] [Related]
5. Using Antigen-Specific B Cells to Combine Antibody and T Cell-Based Cancer Immunotherapy.
Wennhold K; Thelen M; Schlößer HA; Haustein N; Reuter S; Garcia-Marquez M; Lechner A; Kobold S; Rataj F; Utermöhlen O; Chakupurakal G; Theurich S; Hallek M; Abken H; Shimabukuro-Vornhagen A; von Bergwelt-Baildon M
Cancer Immunol Res; 2017 Sep; 5(9):730-743. PubMed ID: 28778961
[TBL] [Abstract][Full Text] [Related]
6. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
7. CD40-activated B cells can efficiently prime antigen-specific naïve CD8+ T cells to generate effector but not memory T cells.
Mathieu M; Cotta-Grand N; Daudelin JF; Boulet S; Lapointe R; Labrecque N
PLoS One; 2012; 7(1):e30139. PubMed ID: 22291907
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic antitumor efficacy of B cells loaded with tumor-derived autophagasomes vaccine (DRibbles).
Ren H; Zhao S; Li W; Dong H; Zhou M; Cao M; Hu HM; Wang LX
J Immunother; 2014 Oct; 37(8):383-93. PubMed ID: 25198526
[TBL] [Abstract][Full Text] [Related]
9. Combined immunization with adjuvant molecules poly(I:C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effects.
Llopiz D; Dotor J; Zabaleta A; Lasarte JJ; Prieto J; Borrás-Cuesta F; Sarobe P
Cancer Immunol Immunother; 2008 Jan; 57(1):19-29. PubMed ID: 17564702
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral interleukin-2/agonist CD40 antibody drives CD4+ -independent resolution of treated-tumors and CD4+ -dependent systemic and memory responses.
Jackaman C; Nelson DJ
Cancer Immunol Immunother; 2012 Apr; 61(4):549-60. PubMed ID: 22002241
[TBL] [Abstract][Full Text] [Related]
11. Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.
Hong S; Li H; Qian J; Yang J; Lu Y; Yi Q
Clin Exp Immunol; 2012 Nov; 170(2):167-77. PubMed ID: 23039887
[TBL] [Abstract][Full Text] [Related]
12. CD40-activated B cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential.
Kondo E; Gryschok L; Klein-Gonzalez N; Rademacher S; Weihrauch MR; Liebig T; Shimabukuro-Vornhagen A; Kochanek M; Draube A; von Bergwelt-Baildon MS
Clin Exp Immunol; 2009 Feb; 155(2):249-56. PubMed ID: 19040609
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
Li Q; Grover AC; Donald EJ; Carr A; Yu J; Whitfield J; Nelson M; Takeshita N; Chang AE
J Immunol; 2005 Aug; 175(3):1424-32. PubMed ID: 16034078
[TBL] [Abstract][Full Text] [Related]
14. Induction of protective cytotoxic T-cell responses by a B-cell-based cellular vaccine requires stable expression of antigen.
Guo S; Xu J; Denning W; Hel Z
Gene Ther; 2009 Nov; 16(11):1300-13. PubMed ID: 19641529
[TBL] [Abstract][Full Text] [Related]
15. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.
Grover A; Kim GJ; Lizée G; Tschoi M; Wang G; Wunderlich JR; Rosenberg SA; Hwang ST; Hwu P
Clin Cancer Res; 2006 Oct; 12(19):5801-8. PubMed ID: 17020987
[TBL] [Abstract][Full Text] [Related]
16. Differential requirements of CD4(+) T-cell signals for effector cytotoxic T-lymphocyte (CTL) priming and functional memory CTL development at higher CD8(+) T-cell precursor frequency.
Umeshappa CS; Nanjundappa RH; Xie Y; Freywald A; Xu Q; Xiang J
Immunology; 2013 Apr; 138(4):298-306. PubMed ID: 23113741
[TBL] [Abstract][Full Text] [Related]
17. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
[TBL] [Abstract][Full Text] [Related]
18. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
[TBL] [Abstract][Full Text] [Related]
19. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
20. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application.
von Bergwelt-Baildon MS; Vonderheide RH; Maecker B; Hirano N; Anderson KS; Butler MO; Xia Z; Zeng WY; Wucherpfennig KW; Nadler LM; Schultze JL
Blood; 2002 May; 99(9):3319-25. PubMed ID: 11964299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
